

# **ADVANCED HEALTH INTELLIGENCE LTD**

## **ACN 602 111 115**

---

### **PROSPECTUS**

---

For the offer of up to 1,000 Shares in the capital of the Company at an issue price of \$0.16 per Share to raise up to \$160 (before expenses) (**Offer**).

#### **IMPORTANT NOTICE**

This document is important and should be read in its entirety. If after reading this Prospectus you have any questions about the Shares being offered under this Prospectus or any other matter, then you should consult your stockbroker, accountant or other professional adviser.

The Shares offered under this Prospectus should be considered speculative.

---

## TABLE OF CONTENTS

---

1.	CORPORATE DIRECTORY .....	1
2.	TIMETABLE AND IMPORTANT NOTES .....	2
3.	DETAILS OF THE OFFER.....	4
4.	PURPOSE AND EFFECT OF THE OFFER.....	7
5.	RIGHTS AND LIABILITIES ATTACHING TO SHARES .....	9
6.	RISK FACTORS .....	12
7.	ADDITIONAL INFORMATION .....	22
8.	DIRECTORS' AUTHORISATION .....	31
9.	DEFINITIONS .....	32

---

## 1. CORPORATE DIRECTORY

### Directors

Mr Nicholas Prosser  
*Non-Executive Chair*

Mr Scott Montgomery  
*Executive Director and CEO*

Dr Katherine Iscoe  
*Executive Director*

Mr Dato Low Koon Poh  
*Non-Executive Director*

Mr Michael Melby  
*Non-Executive Director*

Mr Peter Goldstein  
*Non-Executive Director*

Ms Jacqueline Yee  
*Non-Executive Director*

### Company Secretary and Chief Financial Officer

Mr Simon Durack JP

### Share Registry\*

Automic Registry Services  
Level 5  
191 St Georges Terrace  
PERTH WA 6000

Telephone (within Australia):  
1300 288 664

Telephone (outside Australia):  
+61 2 9698 5414

Email: [hello@ahi.tech](mailto:hello@ahi.tech)

### Registered Office

Unit 5, 71-73 South Perth Esplanade  
SOUTH PERTH WA 6151

Telephone: +61 8 9316 9100

Email: [hello@ahi.tech](mailto:hello@ahi.tech)

Website: [www.ahi.tech](http://www.ahi.tech)

### ASX Code

AHI

### Solicitors

Steinepreis Paganin  
Lawyers and Consultants  
Level 4  
The Read Buildings  
16 Milligan Street  
PERTH WA 6000

### Auditors\*

PKF Brisbane Audit  
6/10 Eagle Street  
BRISBANE CITY QLD 4000

\*These entities have not been involved in the preparation of this Prospectus and have not consented to being named in this Prospectus. Their names are included for information purposes only.

---

## 2. TIMETABLE AND IMPORTANT NOTES

### 2.1 Timetable

Action	Date
Lodgement of Prospectus with the ASIC and ASX	15 June 2023
Opening Date of the Offer	15 June 2023
Closing Date of the Offer*	10:00 am WST on 16 June 2023

\* The Directors reserve the right to bring forward or extend the Closing Date at any time after the Opening Date without notice. As such, the date the Shares are expected to commence trading on ASX may vary with any change in the Closing Date.

### 2.2 Important Notes

This Prospectus is dated 15 June 2023 and was lodged with the ASIC on that date. The ASIC, ASX and their respective officers take no responsibility for the contents of this Prospectus or the merits of the investment to which this Prospectus relates.

No Securities may be issued on the basis of this Prospectus later than 13 months after the date of this Prospectus.

The Offer is only available to those who are personally invited to accept the Offer. Applications for Shares offered pursuant to this Prospectus can only be submitted on an original Application Form that will be provided by the Company, together with a copy of the Prospectus, to selected investors.

This Prospectus is a transaction specific prospectus for an offer of continuously quoted securities (as defined in the Corporations Act) and has been prepared in accordance with section 713 of the Corporations Act. It does not contain the same level of disclosure as an initial public offering prospectus. In making representations in this Prospectus regard has been had to the fact that the Company is a disclosing entity for the purposes of the Corporations Act and certain matters may reasonably be expected to be known to investors and professional advisers whom potential investors may consult.

### 2.3 Web Site – Electronic Prospectus

A copy of this Prospectus can be downloaded from the website of the Company at [www.ahi.tech](http://www.ahi.tech). If you are accessing the electronic version of this Prospectus for the purpose of making an investment in the Company, you must be an Australian resident and must only access this Prospectus from within Australia.

The Corporations Act prohibits any person passing onto another person an Application Form unless it is attached to a hard copy of this Prospectus or it accompanies the complete and unaltered version of this Prospectus. Any person may obtain a hard copy of this Prospectus free of charge by contacting the Company.

The Company reserves the right not to accept an Application Form from a person if it has reason to believe that when that person was given access to the electronic Application Form, it was not provided together with the electronic Prospectus and any relevant supplementary or replacement prospectus or any of those documents were incomplete or altered.

## **2.4 Risk Factors**

Potential investors should be aware that subscribing for Shares in the Company involves a number of risks. The key risk factors of which investors should be aware are set out in Section 6 of this Prospectus. These risks together with other general risks applicable to all investments in listed securities not specifically referred to, may affect the value of the Shares in the future. Accordingly, an investment in the Company should be considered highly speculative. Investors should consider consulting their professional advisers before deciding whether to apply for Shares pursuant to this Prospectus.

## **2.5 Overseas Investors**

The distribution of this Prospectus in jurisdictions outside Australia may be restricted by law and therefore persons into whose possession this document comes should seek advice on and observe any such restrictions. Any failure to comply with these restrictions constitutes a violation of those laws. This Prospectus does not constitute an offer of Shares in any jurisdiction where, or to any person to whom, it would be unlawful to issue in this Prospectus.

## **2.6 Forward-looking statements**

This Prospectus contains forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties.

These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this Prospectus, are expected to take place.

Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of our Company, the Directors and our management.

We cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this prospectus will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

We have no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this prospectus, except where required by law.

These forward looking statements are subject to various risk factors that could cause our actual results to differ materially from the results expressed or anticipated in these statements. These risk factors are set out in Section 6 of this Prospectus.

---

### 3. DETAILS OF THE OFFER

#### 3.1 Offer

Under this Prospectus, the Company invites investors identified by the Directors to apply for up to 1,000 Shares at an issue price of \$0.16 per Share to raise up to \$160 (before expenses).

The Offer will only be extended to specific parties on invitation from the Directors. Application Forms will only be provided by the Company to these parties.

All of the Shares offered under this Prospectus will rank equally with Shares on issue at the date of this Prospectus.

#### 3.2 Objective

The Company is seeking to raise only a nominal amount of \$160 under this Prospectus and, accordingly, the purpose of this Prospectus is not to raise capital.

The primary purpose of this Prospectus is to remove any secondary trading restrictions that may have attached to Shares issued by the Company prior to the Closing Date, including Shares issued as follows:

Relevant Issue	Shares	Issue Date
Shares issued as consideration for short term loan facility	500,000	15 February 2023
Shares issued in consideration for consultancy services provided in connection with the acquisitions of Wellteq Digital Health Inc and Vertica Pty Ltd	400,000	15 February 2023
Shares issued in consideration for services provided by supplier	250,000	18 April 2023
Shares issued to Orca Capital GMBH, an offshore institutional investor ( <b>Capital Raising</b> )	20,000,000	14 June 2023

Relevantly, section 708A(11) of the Corporations Act provides that a sale offer does not need disclosure to investors if:

- (a) the relevant securities are in a class of securities that are quoted securities of the body; and
- (b) either:
  - (i) a prospectus is lodged with the ASIC on or after the day on which the relevant securities were issued but before the day on which the sale offer is made; or
  - (ii) a prospectus is lodged with ASIC before the day on which the relevant securities are issued and offers of securities that have been made under the prospectus are still open for acceptance on the day on which the relevant securities were issued; and
- (c) the prospectus is for an offer of securities issued by the body that are in the same class of securities as the relevant securities.

### 3.3 Application for Shares

Applications for Shares must be made by investors at the direction of the Company and must be made using the Application Form that will be provided by the Company, together with a copy of the Prospectus, to selected investors.

Payment for the Shares must be made in full at the issue price of \$0.16 per Share.

Completed Application Forms and accompanying cheques must be mailed or delivered to the Company as follows:

Delivery by hand	Delivery by post
Unit 5, 71 – 73 South Perth Esplanade SOUTH PERTH WA 6151	Unit 5, 71 – 73 South Perth Esplanade SOUTH PERTH WA 6151

Cheques should be made payable to **“Advanced Health Intelligence Ltd – Share Offer Account”** and crossed **“Not Negotiable”**. Completed Application Forms and cheques must reach the address set out above by no later than the Closing Date.

### 3.4 Minimum subscription

There is no minimum subscription to the Offer.

### 3.5 Underwriter

The Offer is not underwritten.

### 3.6 Issue

Shares issued pursuant to the Offer will be issued in accordance with the ASX Listing Rules and timetable set out at the commencement of this Prospectus.

Where the number of Shares issued is less than the number applied for, or where no issue is made, surplus application monies will be refunded without any interest to the Applicant as soon as practicable after the closing date of the Offer.

Pending the issue of the Shares or payment of refunds pursuant to this Prospectus, all application monies will be held by the Company in trust for the Applicants in a separate bank account as required by the Corporations Act. The Company, however, will be entitled to retain all interest that accrues on the bank account and each Applicant waives the right to claim interest.

Holding statements for Shares issued under the Offer will be mailed in accordance with the timetable set out at the commencement of this Prospectus.

### 3.7 ASX listing

Application for Official Quotation of the Shares offered pursuant to this Prospectus will be made within 7 days of the date of this Prospectus. If ASX does not grant Official Quotation of the Shares offered pursuant to this Prospectus before the expiration of 3 months after the date of issue of the Prospectus, (or such period as varied by the ASIC), the Company will not issue any Shares and will repay all application monies for the Shares within the time prescribed under the Corporations Act, without interest.

The fact that ASX may grant Official Quotation to the Shares is not to be taken in any way as an indication of the merits of the Company or the Shares now offered for subscription.

### **3.8 Applicants outside Australia**

This Prospectus does not, and is not intended to, constitute an offer in any place or jurisdiction, or to any person to whom, it would not be lawful to make such an offer or to issue this Prospectus. The distribution of this Prospectus in jurisdictions outside Australia may be restricted by law and persons who come into possession of this Prospectus should seek advice on and observe any of these restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

No action has been taken to register or qualify the Shares or otherwise permit an offering of the Shares the subject of this Prospectus in any jurisdiction outside Australia. Applicants who are resident in countries other than Australia should consult their professional advisers as to whether any governmental or other consents are required or whether any other formalities need to be considered and followed. If you are outside Australia it is your responsibility to obtain all necessary approvals for the issue of the Shares pursuant to this Prospectus. The return of a completed Application Form will be taken by the Company to constitute a representation and warranty by you that all relevant approvals have been obtained.

### **3.9 Enquiries**

Any questions concerning the Offer should be directed to Simon Durack, Company Secretary, on +61 412 177 478.



## 4. PURPOSE AND EFFECT OF THE OFFER

### 4.1 Purpose of the Offer

The primary purpose of this Prospectus is to remove any trading restrictions that may have attached to Shares issued by the Company prior to the Closing Date (including prior to the date of this Prospectus), including the Share issues outlined in Section 2.2. All of the funds raised from the Offer will be applied towards the expenses of the Offer. Refer to Section 7.8 of this Prospectus for further details relating to the estimated expenses of the Offer.

### 4.2 Effect of the Offer on capital structure

The effect of the Offer on the Company's capital structure is set out below.

Shares	Number
Shares currently on issue	217,203,969
Shares offered under this Prospectus	1,000
<b>Total Shares on issue on completion of the Offer</b>	<b>217,204,969</b>

#### Notes:

1. This table assumes the Offer is fully subscribed and no Options are exercised.
2. As previously announced, the Company has entered into agreements pursuant to which the Company has:
  - (a) acquired a right to acquire up to 40% of the entity that owns Tinjoy Biotech Limited's WinScan Platform, for which consideration will be approximately US\$2-4 million this can be in cash, Shares, or a combination as mutually agreed. The option has yet to be taken up by the Company. For further information, refer to the ASX announcement dated 18 February 2021;
  - (b) agreed to invest a total of up to US\$6,000,000 into Triage Technologies Inc. pursuant to a subscription agreement, comprising US\$3,000,000 in cash (which has been paid) and US\$3,000,000 in Shares. The issue of the Shares is subject to shareholder approval and is intended to be issued in tranches. For further information, refer to the ASX announcement dated 19 April 2021; and
  - (c) raised \$1,976,000 via a convertible note offering to sophisticated investors. At any time after the earlier of (i) 6 months from their date of issue; and (ii) the date that the Company's share price trades at a minimum of \$0.50, a noteholder may elect to convert the principal amount of the notes into Shares at the conversion price equal to the higher of (i) A\$0.50; and (ii) a 25% discount to the volume weighted average price of Shares traded on ASX for the 10 trading days up to and included the trading day prior to the conversion. For further information, refer to the ASX announcement dated 28 April 2023.

The Company does not expect to issue Shares under these agreements during the Offer period.

3. 17,098,200 of the Company's existing Shares are represented by 2,442,600 ADSs, which are listed on the Nasdaq Capital Market.

Options	Number
Unlisted Options exercisable at \$1.60 and expiring on 19 October 2023	4,246,958
Unlisted exercisable at \$0.65 and expiring on 31 December 2023	200,000
Unlisted Options exercisable at \$1.10 and expiring on 18 January 2025	140,000
Unlisted Options exercisable at \$1.50 and expiring on 7 February 2025	700,000
Unlisted Options exercisable at \$0.35 and expiring on 13 June 2025	2,500,000

Options	Number
Options offered under this Prospectus	Nil
<b>Total Options on issue on completion of the Offer</b>	<b>7,786,958</b>

Performance Rights	Number
Performance Rights expiring on 6 November 2026	50,000
Performance Rights offered under this Prospectus	Nil
<b>Total Performance Rights on issue on completion of the Offer</b>	<b>50,000</b>

Warrants	Number
Warrants expiring 24 November 2024	1,007,400 <sup>1</sup>
Warrants offered under this Prospectus	Nil
<b>Total Warrants on issue on completion of the Offer</b>	<b>1,007,400</b>

**Notes:**

1. Each Warrant is exercisable for one ADS. Each ADS represents seven Shares.

### 4.3 Financial effect of the Offer

After expenses of the Offer of approximately \$10,000 there will be no proceeds from the Offer. The expenses of the Offer (exceeding \$160) will be met from the Company's existing cash reserves.

As such, the Offer will have an effect on the Company's financial position, being receipt of funds of \$160 less costs of preparing the Prospectus of approximately \$10,000.

---

## **5. RIGHTS AND LIABILITIES ATTACHING TO SHARES**

The following is a summary of the more significant rights and liabilities attaching to Shares to be issued pursuant to this Prospectus. This summary is not exhaustive and does not constitute a definitive statement of the rights and liabilities of Shareholders. To obtain such a statement, persons should seek independent legal advice.

Full details of the rights and liabilities attaching to Shares are set out in the Company's Constitution, a copy of which is available for inspection at the Company's registered office during normal business hours.

The following is a summary of the more significant rights and liabilities attaching to Shares to be issued pursuant to this Prospectus. This summary is not exhaustive and does not constitute a definitive statement of the rights and liabilities of Shareholders. To obtain such a statement, persons should seek independent legal advice.

Full details of the rights and liabilities attaching to Shares are set out in the Constitution, a copy of which is available for inspection at the Company's registered office during normal business hours.

### **5.1 General meeting and notices**

Each member is entitled to receive notice of, and to attend and vote at, general meetings of the Company and to receive all notices, accounts and other documents required to be sent to members under the Constitution, the Corporations Act or the Listing Rules.

### **5.2 Voting rights**

Subject to any rights or restrictions for the time being attached to any class or classes of shares, at a general meeting of the Company every holder of fully paid ordinary shares present in person or by an attorney; representative or proxy has one vote on a show of hands (unless a member has appointed a proxy) and one vote per share on a poll.

A person who holds a share which is not fully paid is entitled, on a poll, to a fraction of a vote equal to the proportion which the amount paid bears to the total issue price of the share.

Where there are 2 or more joint holders of a share and more than one of them is present at a meeting and tenders a vote in respect of the share, the Company will count only the vote cast by the member whose name appears first in the Company's register of members.

### **5.3 Issues of further Shares**

The Directors may, on behalf of the Company, issue, grant options over unissued shares to any person on the terms, with the rights, and at the times that the Directors decide. However, the Directors must act in accordance with the restrictions imposed by the Constitution, Listing Rules, the Corporations Act and any rights for the time being attached to the shares in any special class of those shares.

## **5.4 Variation of Rights**

Unless otherwise provided by the terms of issue of a class of shares and subject to the Corporations Act, the rights attached to the shares in any class may be varied or cancelled only with the written consent of the holders of at least three-quarters of the issued shares of the affected class, or by special resolution passed at a separate meeting of the holders of the issued shares of the affected class.

## **5.5 Transfer of Shares**

Subject to the Constitution, the Corporations Act and Listing Rules, Shares are freely transferable.

The Shares may be transferred by a proper transfer effected in accordance with the ASX Settlement Operating Rules, by any other method of transferring or dealing with Shares introduced by ASX and as otherwise permitted by the Corporations Act or by a written instrument of transfer in any usual form or in any other form approved by either the Directors or ASX that is permitted by the Corporations Act.

The Directors may decline to register a transfer of Shares (other than a proper transfer in accordance with the ASX Settlement Operating Rules) where permitted to do so under the Listing Rules. If the Directors decline to register a transfer, the Company must, within 5 business days after the transfer is delivered to the Company, give the party lodging the transfer written notice of the refusal and the reason for the refusal. The Directors must decline to register a transfer of Shares when required by law, by the Listing Rules or by the ASX Settlement Operating Rules.

## **5.6 Dividends**

The Directors may from time to time determine dividends to be distributed to members according to their rights and interests. The Directors may fix the time for distribution and the methods of distribution. Subject to the terms of issue of shares, the Company may pay a dividend on one class of shares to the exclusion of another class.

Each share carries the right to participate in the dividend in the same proportion that the amount for the time being paid on the share (not credited) bears to the total amounts paid and payable (excluding amounts credited) in respect of such shares.

## **5.7 Dividend reinvestment and Share plans**

Subject to the requirements in the Corporations Act and the Listing Rules, the Directors may implement and maintain dividend reinvestment plans (under which any member may elect that dividends payable by the Company be reinvested by way of subscription for fully paid shares in the Company).

## **5.8 Capitalisation of profits**

Subject to the Listing Rules and any rights or restrictions attaching to any class of shares, the Company may capitalise profits. Members are entitled to participate in a capital distribution in the same proportions in which they are entitled to participate in dividends.

## **5.9 Winding-up**

Subject to the rights of holders of shares with special rights in a winding-up and the Corporations Act, if the Company is wound up all monies and property that are to be distributed among Shareholders on a winding-up, shall be distributed in proportion to the Shares held by them respectively, irrespective of the amount paid-up or credited as paid-up on the Shares.

## **5.10 Shareholder liability**

As the Shares issued will be fully paid shares, they will not be subject to any calls for money by the Directors and will therefore not become liable for forfeiture.

## **5.11 Alteration of constitution**

In accordance with the Corporations Act, the Constitution can only be amended by a special resolution passed by at least three quarters of Shareholders present and voting at the general meeting. In addition, at least 28 days written notice specifying the intention to propose the resolution as a special resolution must be given.

---

## **6. RISK FACTORS**

### **6.1 Introduction**

The Shares offered under this Prospectus are considered highly speculative. An investment in the Company is not risk free and the Directors strongly recommend potential investors to consider the risk factors described below, together with information contained elsewhere in this Prospectus and to consult their professional advisers before deciding whether to apply for Securities pursuant to this Prospectus.

There are specific risks which relate directly to the Company's business. In addition, there are other general risks, many of which are largely beyond the control of the Company and the Directors. The risks identified in this Section, or other risk factors, may have a material impact on the financial performance of the Company and the market price of the Shares.

The following is not intended to be an exhaustive list of the risk factors to which the Company is exposed.

### **6.2 Company specific**

#### **(a) Achieving profitability**

The Company has only generated very minimal recurring revenues to date as its partner releases have only commenced in late 2020 and losses are expected to continue in the foreseeable future, at least until customer revenue is adequate to fund operating expenses. Successful transition to profitable operations depends on achieving a level of revenues adequate to support the Company's cost structure. However, the Company may be unable to achieve its expected growth or go-live with its product in the anticipated timelines, based on factors outside of its control. Until the Company has ascertained the level of uptake with already contracted partners, this will form part of the Company's focus and process.

#### **(b) Market Acceptance**

The success of the Company's business is highly dependent on market acceptance of its technology and timely release of its technology which is embedded in its partners' customer facing applications. If the end consumer does not accept the Company's product, or customers fail to go live with their applications (with the Company's technology embedded), the Company's financial performance will be materially adversely affected.

The Company expects to derive most of its revenue by charging fees in connection with the usage of its applications and technologies. The Company must make product rollout decisions and commit significant resources well in advance of the anticipated introduction of new applications and technologies. The release of its applications and technologies by its customers (the Company is B2B), while its customers have the relationship with the end user) may be delayed, may not succeed or may have a shorter life cycle than anticipated. If the applications are not released when anticipated or do not attain wide market acceptance, the Company's revenue growth may never materialise, the Company may be unable to fully recover the resources it has committed, and its financial performance will be harmed.

(c) **Intellectual property rights**

A substantial part of the Company's commercial success will depend on its ability to maintain or as the case may be establish, and protect, its intellectual property, maintain trade secret protection and operate without infringing the proprietary rights of third parties.

The Company may be forced to litigate to enforce or defend its intellectual property rights against infringement and unauthorised use by competitors, and to protect our trade secrets. In so doing, the Company's intellectual property may be put at risk of being invalidated, unenforceable, or limited or narrowed in scope. Further, an adverse result in any litigation or defence proceedings may place pending applications at risk of non-issuance. In addition, if any licensor fails to enforce or defend their intellectual property rights, this may adversely affect the Company's ability to develop and commercialise the Company's current and future products and prevent competitors from making, using, and selling competing products. Any such litigation could be very costly and could distract management from focusing on operating the Company's business. Further, because the content of much of the Company's intellectual property concerns cannabis and other activities that are not legal in some state jurisdictions, we may face additional difficulties in defending our intellectual property rights.

If the Company is unable to effectively protect its intellectual property, it may not be able to operate its business and third parties may be able to use and profit from the Company's technology, both of which would impair the Company's ability to be competitive.

(d) **Third party relationship risk**

The Company is dependent in part upon its relationships and alliances with other industry participants. Some of the Company's partners do, or may in the future, assist the Company in the development of its products through licensing, testing, development, or supplier arrangements. If any of the Company's existing relationships with partners were impaired or terminated, or if the Company was unable to implement additional partnering arrangements it may require from time to time, the Company could experience significant delays in the development of its offerings, and would incur additional costs.

(e) **Future acquisitions, strategic investments, partnerships and alliances**

The Company has in the past acquired, and may in the future seek to acquire or invest in, businesses, products or technologies that the Company believes could complement or expand its current client offerings, enhance its technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause the Company to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. The risks the Company faces in connection with such acquisitions include:

- (i) encountering difficulties or unforeseen expenditures in integrating the business, technologies, products, personnel or operations of a company that the Company acquires;

- (ii) an acquisition that disrupts the Company's ongoing business, diverts resources, increases expenses and distracts management;
- (iii) vendor disputes concerning the terms of any acquisition;
- (iv) the Company's use of cash to pay for acquisitions, which would limit other potential uses for its cash;
- (v) if the Company incurs debt to fund an acquisition, such debt may subject it to material restrictions on its ability to conduct its business; and
- (vi) if the Company issues a significant amount of equity securities in connection with acquisitions, existing shareholders may be diluted and earnings per share may decrease.

The occurrence of any of these risks could have an adverse effect on the Company's business, result of operations, financial condition or prospects.

(f) **Dependence on customers**

Whilst the Company establishes commercial contracts with its customers that includes: pricing charges, software development kit (**SDK**) integration audits, and implementation services, and include various options for customer to select from to integrate the Company's technology within their applications to meet their unique business requirements and user experience in the Company's product offering, as well as provide the Company's own design resources to supplement customer design and product teams, the Company has limited control over what price customers offer the integrated solution to end users, as well as where and how the Company's products are integrated into their applications. As a result, customers may set pricing points too high for end users, or design / integrate the Company's application in a sub optimal way that users cannot easily find or use the Company's products, which may substantially impact the Company's ability to generate recurring revenue at the level that it expects.

(g) **Reliance on access to internet**

The Company depends on the ability of its users to access the internet. Access is provided by various classes of entities in the broadband and internet access marketplace. Should any of these entities disrupt, restrict or affect the cost of access to the Company's offerings, usage of these offerings may be negatively impacted.

(h) **Competition risk**

The market in which the Company participates is competitive and characterised by rapid technological change. The Company's potential inability to improve existing product lines and develop new offerings could have a material adverse effect on the Company's business. In addition, the Company's competitors could introduce new products with greater capabilities or better pricing which could have a material adverse effect on the Company's business. Additionally, while the Company will undertake all reasonable due diligence in its business decisions and operations, the Company will have no influence or control



over the activities or actions of its competitors, whose activities or actions may, positively or negatively, affect the operating and financial performance of the Company's business.

(i) **Reliance on key personnel**

The responsibility of overseeing the day-to-day operations and the strategic management of the Company depends substantially on its senior management and its key personnel. There can be no assurance given that there will be no detrimental impact on the Company if one or more of these employees cease their employment.

(j) **Brand maintenance**

The Company believes that maintaining its brand in the mobile health and wellbeing industries is important to maintaining and growing its proposed user base and product acceptance.

This will depend largely on the Company's ability to provide useful and innovative products. The actions of external industry participants may affect the brand if users do not have a positive experience using the Company's offerings, operating systems or devices that provide access to the Company's products.

If the Company fails to maintain its brand, its business and operating results could be adversely affected.

(k) **Open source software**

The Company utilises open source software in its products. The terms of open source licenses to which the Company are subject to may not have been interpreted by Australian or foreign courts, and there is a potential risk that open source software licenses could be construed in a manner that imposes unanticipated conditions or restrictions on the Company's ability to provide or distribute its products.

(l) **Exchange rate movement**

The Company may be exposed to exchange rate movements because some its costs and expenses are from overseas, and revenue it might earn in the future from its product sales may not be paid to the Company in the currency in which it pays the bulk of its expenses or reports its results (currently Australian dollars).

Accordingly, movements in exchange rates may have an impact on the Company's financial position and performance.

Additionally, the Company's Shares are quoted in Australian dollars on the ASX and the ADSs are quoted in U.S. dollars on the NASDAQ Capital Market. Movements in the Australian dollar/U.S. dollar exchange rate may adversely affect the U.S. dollar price of the ADSs. If the Australian dollar weakens against the U.S. dollar, the U.S. dollar price of the ADSs could decline, even if the price of the Company's Shares in Australian dollars increases or remains unchanged.

(m) **Additional requirements for capital**

The Company's capital requirements depend on numerous factors. Depending on the Company's ability to generate income from its operations, the Company will likely require further financing in addition to amounts raised under the capital raising. Any additional equity financing will dilute shareholdings, and debt financing, if available, may involve restrictions on financing and operating activities. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations. There is however no guarantee that the Company will be able to secure any additional funding or be able to secure funding on terms favourable to the Company.

(n) **Climate change risks**

There are a number of climate-related factors that may affect the operations and proposed activities of the Company. The climate change risks particularly attributable to the Company include:

- (i) the emergence of new or expanded regulations associated with the transitioning to a lower-carbon economy and market changes related to climate change mitigation. The Company may be impacted by changes to local or international compliance regulations related to climate change mitigation efforts, or by specific taxation or penalties for carbon emissions or environmental damage. These examples sit amongst an array of possible restraints on industry that may further impact the Company and its profitability. While the Company will endeavour to manage these risks and limit any consequential impacts, there can be no guarantee that the Company will not be impacted by these occurrences; and
- (ii) climate change may cause certain physical and environmental risks that cannot be predicted by the Company, including events such as increased severity of weather patterns and incidence of extreme weather events and longer-term physical risks such as shifting climate patterns. All these risks associated with climate change may significantly change the industry in which the Company operates.

(o) **Potential data breach**

The Company could be harmed by improper disclosure or loss of sensitive or confidential company, employee, associate or customer data, including personal data.

In connection with the operation of the Company's business, the Company plans to store, process and transmit data, including personal information, about its employees, customers, customers' end users, associates and candidates, a portion of which is confidential and/or personally sensitive. Unauthorised disclosure or loss of sensitive or confidential data may occur through a variety of methods. These include, but are not limited to, systems failure, employee negligence, fraud or misappropriation, or unauthorised access to or through the Company's information systems, whether by its employees or third parties, including a cyberattack by computer programmers, hackers, members of organised crime and/or state-sponsored organisations, who may develop and deploy viruses, worms or other malicious software programs.

Such disclosure, loss or breach could harm the Company's reputation and subject the Company to government sanctions and liability under its contracts and laws that protect sensitive or personal data and confidential information, resulting in increased costs or loss of revenues. It is possible that security controls over sensitive or confidential data and other practices the Company and its third-party vendors follow may not prevent the improper access to, disclosure of, or loss of such information. The potential risk of security breaches and cyberattacks may increase as the Company introduces new services and offerings, such as mobile technology. Further, data privacy is subject to frequently changing rules and regulations, which sometimes conflict among the various jurisdictions in which the Company provides services. Any failure or perceived failure to successfully manage the collection, use, disclosure, or security of personal information or other privacy related matters, or any failure to comply with changing regulatory requirements in this area, could result in legal liability or impairment to the Company's reputation in the marketplace.

(p) **Risks related to holding ADSs rather than Shares**

ADS holders do not hold Shares directly and, as such, are subject to, among others, the following additional risks:

- (i) The Company will not treat ADS holders as one of its shareholders and ADS holders will not be able to exercise shareholder rights, except through Bank of New York Mellon (**BNYM**), in its capacity as the Company's Depositary, as permitted by the Deposit Agreement dated 18 November 2021 between the Company, holders of ADSs and BNYM (**Deposit Agreement**).
- (ii) Distributions, if any, on the Shares represented by ADSs will be paid to the Depositary, and before the Depositary makes a distribution to ADS holders, any withholding taxes that must be paid will be deducted. Additionally, if the exchange rate fluctuates during a time when the Depositary cannot convert the foreign currency, ADS holders may lose some or all of the value of the distribution. Any distribution will be paid to ADS holders after deducting the fees and expenses of the Depositary. However, in accordance with the limitations set forth in the Deposit Agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. The Company has no obligation to take any other action to permit the distribution of the ADSs, Shares, rights or anything else to holders of the ADSs.
- (iii) The Company and the Depositary may amend or terminate the Deposit Agreement without the ADS holders' consent in a manner that could prejudice ADS holders.

(q) **Requirements in multiple jurisdictions**

Any actual or perceived failure by the Company to comply with its privacy policy or legal or regulatory requirements in one or multiple jurisdictions could result in proceedings, actions or penalties against the Company.

Any failure or perceived failure by AHL to comply with federal, state or foreign laws or regulations, industry standards, contractual obligations or other legal obligations, or any actual or suspected security incident,

whether or not resulting in unauthorised access to, or acquisition, release or transfer of personal data or other data, may result in governmental enforcement actions and prosecutions, private litigation, fines and penalties or adverse publicity and could cause the Company's customers to lose trust in the Company, which could have an adverse effect on the Company's reputation and business. Any inability to adequately address privacy and security concerns, even if unfounded, or comply with applicable laws, regulations, policies, industry standards, contractual obligations or other legal obligations could result in additional cost and liability to the Company, damage its reputation, inhibit sales and adversely affect its business.

(r) **Coronavirus (COVID-19)**

The outbreak of the coronavirus disease (COVID-19) may continue to impact global economic markets. While COVID-19 is not currently materially affecting the Company's operations, with the potential for further outbreaks and new strains of the virus, the ongoing nature and extent of the effect of the outbreak on the performance of the Company remains unknown. The Company's Share price may be adversely affected in the short to medium term by the economic uncertainty caused by further outbreaks and new strains of COVID19.

Further, any new governmental or industry measures taken in response to COVID-19 may adversely impact the Company's operations and are likely to be beyond the control of the Company.

### **6.3 Industry Specific**

(a) **Technological change**

Technology changes rapidly in the Company's business, and if the Company fails to anticipate new technologies, the quality, timeliness, and competitiveness of its products may suffer.

Rapid technology changes require the Company to anticipate which technologies and/or distribution platforms its products must take advantage of in order to make them competitive in the market at the time they are released. Therefore, the Company usually starts its product development with a range of technical development goals that it hopes to be able to achieve. The Company may not be able to achieve these goals, and even though it has global patent protection, its competition may be able to achieve them more quickly than the Company can. If the Company cannot achieve its technology goals within the original development schedule of its products, this may impact the manner in which users experience its product, which in turn could impact recurring revenue. It may also provide an opportunity for competitors to catch up to the Company.

(b) **User experience risk**

The Company's business model is primarily based on recurring service revenue arising from technology users and customers. Notwithstanding efforts placed on the user interface and experience, a poor user experience may occur and may affect growth of customer numbers and repeat purchases.

(c) **Unforeseen expenditure risk**

Expenditure may need to be incurred, that has not been taken into account in the preparation of this Prospectus. Although the Company is not aware of any such additional expenditure requirements, if such expenditure is subsequently incurred, this may adversely affect the expenditure proposals of the Company.

(d) **Management of growth and strategies**

There is a risk that management of the Company will not be able to implement the Company's strategies, particularly relating to growth, after completion of the Offer. The capacity of the Company's management to properly implement and manage the strategic direction of the Company may affect the Company's financial performance.

(e) **Reliance on third party providers**

While the Company is dependent upon multiple third parties in developing its products, and on its products being able to operate on and with a range of systems, platforms and devices, it is unable to control third party developers of such systems.

Changes to such external platforms, systems or devices may adversely impact on the functionality of the Company's products, and could make customers less likely to use the Company's products, which may have a detrimental impact on the Company's financial performance.

Similarly, the Company's products assume customers are able to access the internet and cellular networks. If third party providers were to raise the cost of these networks, or restrict the ability of customers to access these networks, and thus to use the Company's products, this would be likely to detrimentally affect the Company's financial performance.

(f) **Contractual disputes**

The Company's business model is dependent in part on contractual agreements with third parties that have an interaction with the Company's target market. The Company is aware that there are associated risks when dealing with third parties including but not limited to insolvency, fraud and management failure. Should a third-party contract fail, there is the potential for negative financial and brand damage for the Company.

(g) **Government regulation risk**

The Company is subject to government regulation which may require it to obtain additional licenses and could limit its ability to sell their products. Failure to obtain the requisite licenses (if such licenses are required), meet registration standards or comply with other government export regulations, may affect the Company's ability to export such products or to generate revenues from the sale of products internationally, which could have a material adverse effect on the Company's business, financial condition and results of operations. Compliance with government regulations may also subject the Company to additional fees and costs.

The absence of comparable restrictions on competitors in other countries may adversely affect the Company's competitive position.

## **6.4 General Risks**

### **(a) Economic conditions and other global or national issues**

General economic conditions, laws relating to taxation, new legislation, trade barriers, movements in interest and inflation rates, currency exchange controls and rates, national and international political circumstances (including wars, terrorist acts, sabotage, subversive activities, security operations, labour unrest, civil disorder, and states of emergency), natural disasters (including fires, earthquakes and floods), and quarantine restrictions, epidemics and pandemics, may have an adverse effect on the Company's operations.

General economic conditions may also affect the value of the Company and its market valuation regardless of its actual performance.

Specifically, it should be noted that the current evolving conflict between Ukraine and Russia is impacting global macroeconomics and markets generally. The nature and extent of the effect of this conflict on the performance of the Company and the value of the Company's Shares remains unknown. The Company's Share price may be adversely affected in the short to medium term by the economic uncertainty caused by the conflict between Ukraine and Russia and overall impacts on global macroeconomics. Given the situation is continually evolving, the outcomes and consequences are inevitably uncertain.

### **(b) Market conditions**

Share market conditions may affect the value of the Company's quoted securities regardless of the Company's operating performance. Share market conditions are affected by many factors such as:

- (i) general economic outlook;
- (ii) introduction of tax reform or other new legislation;
- (iii) interest rates and inflation rates;
- (iv) changes in investor sentiment toward particular market sectors;
- (v) the demand for, and supply of, capital; and
- (vi) terrorism or other hostilities.

The market price of securities can fall as well as rise and may be subject to varied and unpredictable influences on the market for equities in general and biotechnology stocks in particular. Neither the Company nor the Directors warrant the future performance of the Company or any return on an investment in the Company.

(c) **Litigation or disputes**

The Company is exposed to possible litigation risks including intellectual property claims, contractual disputes and employee claims. Further, the Company may, from time to time, be involved in legal proceedings or disputes with a variety of parties, including, but not limited to, employees, major shareholders, former employees, government agencies or regulators, end-consumers, customers, vendors or suppliers arising in the ordinary course of business or otherwise. The Directors do not believe that any claim by a former employee would be successful or material to the financial position of the Company. However, the outcome of litigation or a dispute cannot be predicted with certainty and any such claim or dispute, if proven, may impact adversely on the Company's operations. Refer to Section 7.2 for further information.

**6.5 Speculative investment**

The above list of risk factors ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company. The above factors, and others not specifically referred to above, may in the future materially affect the financial performance of the Company and the value of the Shares offered under this Prospectus.

Therefore, the Shares to be issued pursuant to this Prospectus carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares.

Potential investors should consider that the investment in the Company is speculative and should consult their professional advisers before deciding whether to apply for Shares pursuant to this Prospectus.

---

## **7. ADDITIONAL INFORMATION**

### **7.1 Excluded information**

The Company notes that it is continually in discussions with various parties, including its existing technology partners, with respect to potential acquisitions or licensing arrangements in relation to technology which may be complementary to the Company's existing CompleteScan platform. Such potential acquisitions or licensing arrangements are not announced until such time as the Company has agreed the material commercial terms with the relevant counterparty or counterparties. Until the material commercial terms have been agreed, there can be no guarantee that such discussions, whether or not they have been disclosed, will lead to the announcement or completion of a binding acquisition or licensing agreement.

As announced on 28 April 2023, the Company has as at the date of this Prospectus raised \$1,976,000 via a convertible note offering to sophisticated investors. The Company is seeking to raise up to USD\$10,000,000 under the facility and is currently in discussions with a number of parties regarding the balance of the raise. Until the material commercial terms have been agreed for the balance of the raise, there can be no guarantee that such discussions, whether or not they have been disclosed, will lead to completion of the capital raising.

### **7.2 Litigation**

The Company have been advised by the Fair Work Commission (FWC) that a former employee of the Company has commenced a general protections application in relation to their dismissal. The Company is yet to receive a copy of the application, and will update the market of any material developments with respect to this matter.

Otherwise, as at the date of this Prospectus, the Company is not involved in any legal proceedings and the Directors are not aware of any legal proceedings pending or threatened against the Company.

### **7.3 Continuous disclosure obligations**

The Company is a "disclosing entity" (as defined in section 111AC of the Corporations Act) for the purposes of section 713 of the Corporations Act and, as such, is subject to regular reporting and disclosure obligations. Specifically, like all listed companies, the Company is required to continuously disclose any information it has to the market which a reasonable person would expect to have a material effect on the price or the value of the Company's securities.

This Prospectus is a "transaction specific prospectus". In general terms a "transaction specific prospectus" is only required to contain information in relation to the effect of the issue of securities on the Company and the rights attaching to the securities. It is not necessary to include general information in relation to all of the assets and liabilities, financial position, profits and losses or prospects of the issuing company.

This Prospectus is intended to be read in conjunction with the publicly available information in relation to the Company which has been notified to ASX and does not include all of the information that would be included in a prospectus for an initial public offering of securities in an entity that is not already listed on a stock exchange. Investors should therefore have regard to the other publicly available information in relation to the Company before making a decision whether or not to invest.



Having taken such precautions and having made such enquires as are reasonable, the Company believes that it has complied with the general and specific requirements of ASX as applicable from time to time throughout the 3 months before the issue of this Prospectus which required the Company to notify ASX of information about specified events or matters as they arise for the purpose of ASX making that information available to the stock market conducted by ASX.

Information that is already in the public domain has not been reported in this Prospectus other than that which is considered necessary to make this Prospectus complete.

The Company, as a disclosing entity under the Corporations Act states that:

- (a) it is subject to regular reporting and disclosure obligations;
- (b) copies of documents lodged with the ASIC in relation to the Company (not being documents referred to in section 1274(2)(a) of the Corporations Act) may be obtained from, or inspected at, the offices of the ASIC; and
- (c) it will provide a copy of each of the following documents, free of charge, to any person on request between the date of issue of this Prospectus and the Closing Date:
  - (i) the annual financial report most recently lodged by the Company with the ASIC;
  - (ii) any half-year financial report lodged by the Company with the ASIC after the lodgement of the annual financial report referred to in (i) and before the lodgement of this Prospectus with the ASIC; and
  - (iii) any continuous disclosure documents given by the Company to ASX in accordance with the ASX Listing Rules as referred to in section 674(1) of the Corporations Act after the lodgement of the annual financial report referred to in (i) and before the lodgement of this Prospectus with the ASIC.

Other than as set out in Section 7.1, there is no information which has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules that investors or their professional advisers:

- (a) would reasonably require for the purpose of making an informed assessment of the:
  - (i) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; and
  - (ii) the rights and liabilities attaching to the Shares the subject of this Prospectus; and
- (b) would reasonably expect to find in this Prospectus.

This Prospectus contains information specific to the Offer. If investors require further information in relation to the Company, they are recommended to take advantage of the opportunity to inspect or obtain copies of the documents referred to below.

Copies of all documents lodged with the ASIC in relation to the Company can be inspected at the registered office of the Company or an ASIC office during normal office hours.

Details of documents lodged with ASX since the date of lodgement of the Company's latest annual financial report and before the lodgement of this Prospectus with the ASIC are set out in the table below:

Date	Description of Announcement
14/06/2023	Notification regarding unquoted securities - AHI
14/06/2023	Application for quotation of securities - AHI
13/06/2023	Proposed issue of securities - AHI
13/06/2023	Response to ASX Price Query
13/06/2023	AHI Announces AUD\$5 million Private Placement
13/06/2023	Trading Halt
13/06/2023	Pause in Trading
2/6/2023	Update - Application for quotation of securities - AHI
30/5/2023	AHI Executes Formal Agreement with Kalibra Pte Ltd
19/5/2023	Response to ASX Price and Volume Query
28/4/2023	AHI Quarterly Commentary and Cash Flow
28/4/2023	Proposed issue of securities - AHI
28/4/2023	AHI Secures Convertible Note Facility
24/4/2023	Change in substantial holding
18/4/2023	Application for quotation of securities - AHI
23/3/2023	Change of Director's Interest Notice
8/3/2023	AHI Company Presentation
8/3/2023	AHI Shareholder Update
28/2/2023	Half Yearly Report and Accounts
17/2/2023	Update - Application for quotation of securities - AHI
15/2/2023	Application for quotation of securities - AHI
15/2/2023	Application for quotation of securities - AHI
14/2/2023	AHI Executes Formal Agreement with Augmented Reality Concie
8/2/2023	AHI Announces End of Voluntary Escrow Period
7/2/2023	AHI Files SEC Form 20-F & Meets NASDAQ Compliance Requirement
31/1/2023	AHI Quarterly Commentary and Cash Flow
30/1/2023	Proposed issue of securities - AHI
30/1/2023	AHI Secures R & D Grant and Short Term Loan Facility
25/1/2023	AHI Concludes Formal Agreements with Upvio Healthtech
13/1/2023	Notification of cessation of securities - AHI
3/1/2023	Change in substantial holding

Date	Description of Announcement
28/12/2022	Becoming a substantial holder
28/12/2022	Change of Director's Interest Notice
23/12/2022	Response to ASX 3X Query
23/12/2022	AHI Granted 180 Day Extension to NASDAQ Re-compliance
22/12/2022	Initial Director's Interest Notice
20/12/2022	Application for quotation of securities - AHI
20/12/2022	Final Director's Interest Notice
20/12/2022	AHI Strengthens Board Further
19/12/2022	Initial Director's Interest Notice
15/12/2022	AHI Releases Reissued 2022 Annual Report
9/12/2022	AHI Bolsters Board
9/12/2022	AHI Expands Digital Health Portfolio and Changes Name
8/12/2022	Change in substantial holding
7/12/2022	AHI Confirms Completion of wellteq Plan of Arrangement
7/12/2022	wellteq Consideration Shares Issued
6/12/2022	Proposed issue of securities - AHI
6/12/2022	Appendix 2A
1/12/2022	wellteq Acquisition Update
1/12/2022	AHI Announces New Appointments and Resignation
29/11/2022	Results of Meeting
25/11/2022	wellteq Shareholders Vote in Favour of Acquisition by AHI
24/11/2022	AHI Announces End of Voluntary Escrow Period
23/11/2022	AHI Receives Deficiency Letter from NASDAQ
23/11/2022	Change in substantial holding
2/11/2022	AHI Corporate Governance Statement
1/11/2022	AHI Quarterly Report and Appendix 4C
1/11/2022	Appendix 4G
31/10/2022	2022 Annual General Meeting Notice
27/10/2022	wellteq Acquisition Update
13/10/2022	Reinstatement to Official Quotation

ASX maintains files containing publicly available information for all listed companies. The Company's file is available for inspection at ASX during normal office hours.

The announcements are also available through the Company's website [www.ahi.tech](http://www.ahi.tech).

## 7.4 Market price of Shares

The Company is a disclosing entity for the purposes of the Corporations Act and its Shares are enhanced disclosure securities quoted on ASX.

The highest, lowest and last market sale prices of the Shares on ASX during the three months immediately preceding the date of lodgement of this Prospectus with the ASIC and the most recent dates of those sales were:

	Price	Date
Highest	\$0.40	13 June 2023
Lowest	\$0.075	3 May 2023, 9 May 2023, 15 May 2023 to 18 May 2023
Last	\$0.16	15 June 2023

## 7.5 Details of substantial holders

Based on publicly available information as at the date of this Prospectus, those persons which (together with their associates) have a relevant interest in 5% or more of the Shares on issue are set out below:

Shareholder	Shares	%
Dr Katherine Iscoe <sup>1</sup>	34,291,864	15.79%
The Bank of New York Mellon Corporation <sup>2</sup>	18,584,596	8.56%

**Note:**

1. Of which 17,391,864 are held directly by Dr Katherine Iscoe, an Executive Director, and 16,900,000 are held by Mad Scientist Pty Ltd (an entity controlled by Dr Iscoe).
2. The Bank of New York Mellon Corporation is the ultimate parent company of a corporate group comprised of a large number of operating and holding companies, including The Bank of New York Mellon (**BNYM**). BNYM holds the limited power to dispose of, or control the exercise of a power to dispose of, securities deposited with or held by BNYM (or its custodian or agent) in its capacity as depositary administering an American Depositary Receipts (**ADR**) program for the Company under the Deposit Agreement dated 18 November 2021 between the Company, holders of ADRs and BNYM (**Deposit Agreement**). Under the Deposit Agreement, ADR holders retain their rights to dispose of those securities and to give voting instructions for the exercise of voting rights attached to the securities. BNYMC Group's power to vote or dispose of these securities is qualified accordingly.

## 7.6 Directors' Interests

Other than as set out below or elsewhere in this Prospectus, no Director nor any firm in which such a Director is a partner, has or had within 2 years before the lodgement of this Prospectus with the ASIC, any interest in:

- (a) the formation or promotion of the Company;
- (b) property acquired or proposed to be acquired by the Company in connection with its formation or promotion or the Offer pursuant to this Prospectus; or
- (c) the Offer,

and no amounts have been paid or agreed to be paid (in cash or Shares or otherwise) to any Director or to any firm in which any such Director is a partner or director, either to induce them to become, or to qualify them as, a Director or otherwise for services rendered by them or by the firm in connection with the formation or promotion of the Company or the Offer.

### **Security holdings**

The relevant interest of each of the Directors in the securities of the Company as at the date of this Prospectus is set out in the table below.

Director	Shares	Options
Mr Scott Montgomery	616,410	Nil
Dr Katherine Iscoe	34,291,864 <sup>1</sup>	Nil
Mr Dato Koon Poh Low	300,000	Nil
Mr Nicholas Prosser	7,265,036 <sup>2</sup>	Nil
Mr Michael Melby	4,000,000 <sup>3</sup>	Nil
Mr Peter Goldstein	Nil	140,000 <sup>4</sup>
Ms Jacqueline Yee	Nil	Nil

#### **Notes:**

1. Comprising 16,900,000 Shares held indirectly by Mad Scientist Pty Ltd, an entity controlled by Dr Katherine Iscoe, and 17,391,864 Shares held directly by Dr Katherine Iscoe.
2. Comprising 6,515,036 Shares held directly by Mr Prosser and 750,000 Shares held indirectly by Gated Prospect Pty Ltd in which Mr Prosser has voting power of over 20%.
3. Held indirectly by Fitlab Fund Management, LLC in which Mr Melby holds a 50% ownership and is the co-managing partner.
4. Exercisable at \$1.10 on or before 18 January 2025 held indirectly by Exchange Listing LLC, in which Mr Goldstein is the CEO and founder.

### **Remuneration**

The remuneration of an executive Director is decided by the Board, without the affected executive Director participating in that decision-making process. The total maximum remuneration of non-executive Directors is initially set by the Constitution and subsequent variation is by ordinary resolution of Shareholders in general meeting in accordance with the Constitution, the Corporations Act and the ASX Listing Rules, as applicable. The determination of non-executive Directors' remuneration within that maximum will be made by the Board having regard to the inputs and value to the Company of the respective contributions by each non-executive Director. The current amount has been set at an amount not to exceed \$300,000 per annum.

A Director may be paid fees or other amounts (ie non-cash performance incentives such as Options, subject to any necessary Shareholder approval) as the other Directors determine where a Director performs special duties or otherwise performs services outside the scope of the ordinary duties of a Director. In addition, Directors are also entitled to be paid reasonable travelling, hotel and other expenses incurred by them respectively in or about the performance of their duties as Directors.

The following table shows the total (and proposed) annual remuneration paid to both executive and non-executive directors.

Director	Remuneration for year ended 30 June 2021	Remuneration for year ended 30 June 2022	Proposed remuneration for year ending 30 June 2023 <sup>1</sup>
Mr Scott Montgomery <sup>1</sup>	Nil	Nil	\$204,167 <sup>4</sup>
Dr Katherine Iscoe	Nil	\$71,965	\$249,000
Mr Dato Koon Poh Low	\$34,956	\$36,000	\$36,000
Mr Nicholas Prosser	\$2,894,420	\$499,475	\$36,000 <sup>5</sup>
Mr Michael Melby	\$1,101,000	\$496,000	\$51,628 <sup>5,6</sup>
Mr Peter Goldstein <sup>2</sup>	Nil	Nil	\$51,628 <sup>6</sup>
Ms Jacqueline Yee <sup>3</sup>	Nil	Nil	\$18,000 <sup>7</sup>

**Notes:**

1. Appointed as a Director on 1 December 2022.
2. Appointed as a Director on 29 June 2022.
3. Appointed as a Director on 20 December 2022.
4. \$350,000 per annum.
5. The Company is proposing, subject to Shareholder approval, to issue 1,000,000 Shares to each of Mr Melby and Mr Prosser.
6. Being US\$36,000 based on a A\$0.6973:US\$1 exchange rate.
7. \$36,000 per annum.

Other than as set out below or elsewhere in this Prospectus, no:

- (a) person named in this Prospectus as performing a function in a professional, advisory or other capacity in connection with the preparation or distribution of this Prospectus;
- (b) promoter of the Company; or
- (c) underwriter (but not a sub-underwriter) to the issue or a financial services licensee named in this Prospectus as a financial services licensee involved in the issue,

holds, or has held within the 2 years preceding lodgement of this Prospectus with the ASIC, any interest in:

- (d) the formation or promotion of the Company;
- (e) any property acquired or proposed to be acquired by the Company in connection with:
  - (i) its formation or promotion; or
  - (ii) the Offer; or
- (f) the Offer,

and no amounts have been paid or agreed to be paid and no benefits have been given or agreed to be given to any of these persons for services provided in connection with:

- (g) the formation or promotion of the Company; or
- (h) the Offer.

Steinepreis Paganin has acted as the solicitors to the Company in relation to the Offer. The Company estimates it will pay Steinepreis Paganin \$5,000 (excluding GST and disbursements) for these services. During the 24 months preceding lodgement of this Prospectus with the ASIC, Steinepreis Paganin has been paid fees totalling \$312,846 (excluding GST and disbursements) for legal services provided to the Company.

## 7.7 Consents

Chapter 6D of the Corporations Act imposes a liability regime on the Company (as the offeror of the Securities), the Directors, the persons named in the Prospectus with their consent as Proposed Directors, any underwriters, persons named in the Prospectus with their consent having made a statement in the Prospectus and persons involved in a contravention in relation to the Prospectus, with regard to misleading and deceptive statements made in the Prospectus. Although the Company bears primary responsibility for the Prospectus, the other parties involved in the preparation of the Prospectus can also be responsible for certain statements made in it.

Each of the parties referred to in this Section:

- (a) does not make, or purport to make, any statement in this Prospectus other than those referred to in this Section; and
- (b) in light of the above, only to the maximum extent permitted by law, expressly disclaims and takes no responsibility for any part of this Prospectus other than a reference to its name and a statement included in this Prospectus with the consent of that party as specified in this Section.

Steinepreis Paganin has given its written consent to being named as the solicitors to the Company in this Prospectus. Steinepreis Paganin has not withdrawn its consent prior to the lodgement of this Prospectus with the ASIC.

## 7.8 Estimated expenses of Offer

The total expenses of the Offer are estimated to be approximately \$10,000 as follows:

Expense	(\$)
ASIC Fees	3,206
ASX Fees	1,250
Legal Fees	5,000
Miscellaneous and other expenses	544
<b>Total</b>	<b>10,000</b>

## **7.9 Electronic Prospectus**

ASIC has exempted compliance with certain provisions of the Corporations Act to allow distribution of an electronic prospectus and electronic application form on the basis of a paper prospectus lodged with the ASIC, and the publication of notices referring to an electronic prospectus or electronic application form, subject to compliance with certain conditions.

If you have received this Prospectus as an electronic Prospectus, please ensure that you have received the entire Prospectus accompanied by the Application Form. If you have not, please contact the Company at [hello@ahi.tech](mailto:hello@ahi.tech) and the Company will send you, for free, either a hard copy or a further electronic copy of the Prospectus, or both.

The Company reserves the right not to accept an Application Form from a person if it has reason to believe that when that person was given access to the electronic Application Form, it was not provided together with the electronic Prospectus and any relevant supplementary or Prospectus or any of those documents were incomplete or altered.

## **7.10 Clearing House Electronic Sub-Register System (CHES) and Issuer Sponsorship**

The Company will not be issuing Share certificates. The Company is a participant in CHES, for those investors who have, or wish to have, a sponsoring stockbroker. Investors who do not wish to participate through CHES will be issuer sponsored by the Company. Because the sub-registers are electronic, ownership of securities can be transferred without having to rely upon paper documentation.

Electronic registers mean that the Company will not be issuing certificates to investors. Instead, investors will be provided with a statement (similar to a bank account statement) that sets out the number of Shares issued to them under this Prospectus. The notice will also advise holders of their Holder Identification Number or Security Holder Reference Number and explain, for future reference, the sale and purchase procedures under CHES and issuer sponsorship.

Further monthly statements will be provided to holders if there have been any changes in their security holding in the Company during the preceding month.

## **7.11 Privacy Act**

If you complete an application for Shares, you will be providing personal information to the Company. The Company collects, holds and will use that information to assess your application, service your needs as a Shareholder, facilitate distribution payments and corporate communications to you as a Shareholder and carry out administration.

The information may also be used from time to time and disclosed to persons inspecting the register, bidders for your securities in the context of takeovers, regulatory bodies, including the Australian Taxation Office, authorised securities brokers, print service providers, mail houses and the Company's Share Registry.

You can access, correct and update the personal information that we hold about you. Please contact the Company if you wish to do so at the relevant contact numbers set out in this Prospectus.

Collection, maintenance and disclosure of certain personal information is governed by legislation including the *Privacy Act 1988* (Cth) (as amended), the Corporations Act and certain rules such as the ASX Settlement Operating Rules. You should note that if you do not provide the information required on the application for Shares, the Company may not be able to accept or process your application.



---

**8. DIRECTORS' AUTHORISATION**

This Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors.

In accordance with section 720 of the Corporations Act, each Director has consented to the lodgement of this Prospectus with the ASIC.

---

**Nicholas Prosser**  
**Non-Executive Chair**  
**For and on behalf of**  
**Advanced Health Intelligence Ltd**

---

## 9. DEFINITIONS

**\$** means Australian dollars.

**ADS** means an American depositary share, each of which represents seven Shares.

**Applicant** means an investor who applies for Shares pursuant to the Offer.

**Application Form** means an application form accompanying this Prospectus.

**ASIC** means the Australian Securities and Investments Commission.

**ASX** means ASX Limited (ACN 008 624 691) or the financial market operated by it, as the context requires.

**ASX Listing Rules** means the listing rules of the ASX.

**ASX Settlement Operating Rules** means the settlement rules of the securities clearing house which operates CHESS.

**Board** means the board of Directors unless the context indicates otherwise.

**Business Day** means Monday to Friday inclusive, except New Year's Day, Good Friday, Easter Monday, Christmas Day, Boxing Day and any other day that ASX declares is not a business day.

**Capital Raising** has the meaning given in Section 3.2 of this Prospectus.

**Closing Date** means the date specified in the timetable in Section 2.1 of this Prospectus (unless extended or brought forward).

**Company** or **the Company** means Advanced Health Intelligence Ltd (ACN 602 111 115).

**Constitution** means the constitution of the Company as at the date of this Prospectus.

**Corporations Act** means the *Corporations Act 2001* (Cth).

**Directors** means the directors of the Company as at the date of this Prospectus.

**Offer** means the offer of up to 1,000 Shares at an issue price of \$0.16 per Share to raise up to \$160.

**Official Quotation** means official quotation on ASX.

**Opening Date** means the opening date of the Offer as specified in the timetable set out in Section 2.1 of this Prospectus (unless varied).

**Option** means an option to acquire a Share.

**Prospectus** means this prospectus.

**Section** means a section of this Prospectus.

**Securities** means Shares and Options.

**Share** means a fully paid ordinary share in the capital of the Company.

**Shareholder** means a shareholder of the Company.

**WST** means western standard time as observed in Perth, Western Australia.